Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05975983 · ClinicalTrials.gov registry record · Phase 2

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

A Phase 2 study of Idiopathic Pulmonary Fibrosis (IPF), sponsored by InSilico Medicine Hong Kong Limited.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
12
Study locations

NCT05975983 is a Phase 2 study of Idiopathic Pulmonary Fibrosis (IPF) that is actively recruiting participants, run by InSilico Medicine Hong Kong Limited. The registered enrollment target is 40 participants, below the 492-participant average among 8 other Idiopathic Pulmonary Fibrosis (IPF) trials with a reported enrollment target (92% lower). The trial reports 12 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05975983, a Phase 2 study of Idiopathic Pulmonary Fibrosis (IPF), is actively recruiting participants, sponsored by InSilico Medicine Hong Kong Limited.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
12
Study locations

Study Summary

The purpose of this revised Phase IIa study is to demonstrate safety of INS018\_055 over 12 weeks in adults with Idiopathic Pulmonary Fibrosis (IPF).

Conditions Studied

Idiopathic Pulmonary Fibrosis (IPF)

Interventions

  • DRUG Placebo
  • DRUG INS018_055

Study Locations (12)

Texas

  • University of Texas Southwestern Medical Center - Dallas
  • Metroplex Pulmonary and Sleep Center - McKinney
  • Research Centers of America - McKinney

Florida

  • Florida Lung Asthma and Sleep Specialist - Celebration
  • Central Florida Pulmonary Group, P.A. (CFPG) - Downtown Orlando - Orlando

Alabama

  • University of Alabama at Birmingham - Birmingham

Arizona

  • HonorHealth Research Institute - Scottsdale

California

  • Keck School of Medicine of USC - Los Angeles

North Carolina

  • Southeastern Research Center - Winston-Salem

Oklahoma

  • University of Oklahoma Health Sciences Center (OUHSC) - Oklahoma City

Pennsylvania

  • Temple University Hospital-Temple Lung Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-02-08
Est. Completion 2026-02-28
Phase Phase 2

Sponsor

InSilico Medicine Hong Kong Limited

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05975983

The ClinicalTrials.gov registry entry for NCT05975983 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 492-participant average among 8 other Idiopathic Pulmonary Fibrosis (IPF) trials with a reported enrollment target (92% lower). The listed sponsor is InSilico Medicine Hong Kong Limited, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Idiopathic Pulmonary Fibrosis (IPF) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05975983 reports 12 study locations spanning 9 distinct geographic areas - top geographies include Texas, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT05975983 about?

NCT05975983 is a clinical study titled "Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis". The purpose of this revised Phase IIa study is to demonstrate safety of INS018\_055 over 12 weeks in adults with Idiopathic Pulmonary Fibrosis (IPF).

What is the current status of trial NCT05975983?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-02-08. Estimated completion is 2026-02-28.

What conditions does trial NCT05975983 study?

This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis (IPF).

What interventions are being tested in trial NCT05975983?

The interventions under investigation include: Placebo (DRUG), INS018_055 (DRUG).

Who is sponsoring clinical trial NCT05975983?

This trial is sponsored by InSilico Medicine Hong Kong Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05975983 being conducted?

This trial has 12 study locations across Alabama, Arizona, California, Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Idiopathic Pulmonary Fibrosis (IPF)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Idiopathic Pulmonary Fibrosis (IPF)

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.